HTB

No benefit from TDF/FTC against COVID-19

Simon Collins, HIV i-Base

Results from this open-label, double-randomised, phase 3 study in 355 participants (97% hospitalised at baseline), reported no benefits from TDF/FTC or from baricitinib on 28-day moprtality.

Reference

Montejano R et al. on behalf of the PANCOVID study Group, Tenofovir disoproxil fumarate/emtricitabine and baricitinib for patients at high risk of severe COVID-19: The PANCOVID Randomized Clinical Trial, Clinical Infectious Diseases, 2022; ciac628, doi:10.1093/cid/ciac628. (30 July 2022).
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac628/6652179

Links to other websites are current at date of posting but not maintained.